机构：[1]Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China河北医科大学第四医院[2]Hebei Med Univ, Hosp 4, Dept Hematol, Shijiazhuang, Peoples R China临床科室血液内科河北医科大学第四医院[3]Hebei Med Univ, Hosp 4, Hebei Tumor Hosp, Dept Hematol, Shijiazhuang, Peoples R China临床科室血液内科河北医科大学第四医院[4]Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
第一作者机构：[1]Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China
推荐引用方式(GB/T 7714)：
Bai Yan,Gao Yuhuan,Liu Lihong,et al.Clinical Efficacy and Safety Evaluation of Isazomib Based Combination Regimen for Multiple Myeloma First-Line Therapy[J].BLOOD.2024,144:7029-7030.doi:10.1182/blood-2024-205537.
APA：
Bai, Yan,Gao, Yuhuan,Liu, Lihong,Diao, Lanping,Wu, Xiaolin...&Huang, Chen.(2024).Clinical Efficacy and Safety Evaluation of Isazomib Based Combination Regimen for Multiple Myeloma First-Line Therapy.BLOOD,144,
MLA：
Bai, Yan,et al."Clinical Efficacy and Safety Evaluation of Isazomib Based Combination Regimen for Multiple Myeloma First-Line Therapy".BLOOD 144.(2024):7029-7030
医学